← All stocks

Candel Therapeutics, Inc.

CADL Scheduled selling only
CIK 0001841387 #2585 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$3.24M
$704.89K on a plan · $2.54M straight out of an exercise
Sold at will
$0.00
0 of 3 sales
Net
−$3.24M
$0.00 against sales at will

By person

11 insiders · 3 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Tak Paul Peter
Chief Executive Officer
$3.16M (2) scheduled
−$3.16M
113,321
$1.18M
−65.7%
Tyagarajan Seshu
Chief Technology Officer
$84.00K (1) scheduled
−$84.00K
76,865
$803.73K
−53.7%
Manning Paul B
Director
2,763,527
$28.90M
Aguilar-Cordova Estuardo
10% owner
283,790
$2.97M
−85.0%
Martell Christopher
Director
111,349
$1.16M
Barone Francesca
Chief Scientific Officer
77,362
$808.93K
−51.6%
PAPA JOSEPH C
Director
64,239
$671.71K
Nichols William Garrett
Chief Medical Officer
52,493
$548.89K
−54.1%
Schoch Charles
Chief Financial Officer
43,391
$453.71K
−30.6%
Nabel Gary J.
Director
5,353
$55.97K
Loggia Nicoletta
Director
2,141
$22.39K

No percentages here. This company's share count has moved by a factor of 2.4 over the window, from 32,475,537 to 76,518,565 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Tak Paul Peter
10 Sep 2026
Chief Executive Officer
Sold after exercise
220,866
$11.50
$2.54M

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 1
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 125,000
History held since 29 Jul 2021